Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis
- PMID: 20019362
- DOI: 10.1167/iovs.09-4638
Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis
Abstract
Purpose: To determine the minimum inhibitory concentrations (MICs) of 12 antimicrobials in current ophthalmic use and 4 potentially new alternatives against isolates from bacterial keratitis.
Methods: Bacteria were collected from cases of bacterial keratitis in six centers in the United Kingdom between 2003 and 2006. MICs were measured by using susceptibility strips containing a concentration gradient of the antimicrobials penicillin, cefuroxime, ceftazidime, chloramphenicol, gentamicin, amikacin, vancomycin, teicoplanin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, meropenem, linezolid, tigecycline, and daptomycin.
Results: Isolates (n = 772) were collected including coagulase negative Staphylococcus (CNS) (30%), Pseudomonas aeruginosa (23%), Staphylococcus aureus (14%), Enterobacteriaceae (14%), and streptococci (13%). Meropenem had low MICs for most isolates. All isolates except P. aeruginosa were susceptible to tigecycline. Linezolid was active against the majority of Gram-positive pathogens. Ten percent of S. aureus and 20% of CNS isolates were methicillin resistant. When systemic breakpoints were used, 84% of S. aureus isolates were susceptible to ciprofloxacin and 98% to moxifloxacin. Of the P. aeruginosa isolates, 99% were susceptible to ceftazidime, 96% to gentamicin, 99% to ciprofloxacin and 100% to moxifloxacin. More than 97% of Enterobacteriaceae isolates were susceptible to ceftazidime, gentamicin, ciprofloxacin, and moxifloxacin.
Conclusions: Based on systemic breakpoint data, resistance to commonly used antimicrobials was apparent. Meropenem is a potentially effective agent for ophthalmic use, with low MICs throughout all the bacterial subgroups. Tigecycline and linezolid showed good activity against particular groups and may be useful for treating bacterial keratitis resistant to current antimicrobials. Of the fluoroquinolones, moxifloxacin showed the lowest MICs and resistance for both Gram-positive and -negative bacteria.
Similar articles
-
An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis.Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4151-5. doi: 10.1167/iovs.09-4839. Epub 2010 Mar 24. Invest Ophthalmol Vis Sci. 2010. PMID: 20335613
-
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.Am J Ophthalmol. 2004 Aug;138(2):226-30. doi: 10.1016/j.ajo.2004.03.016. Am J Ophthalmol. 2004. PMID: 15289131
-
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.Diagn Microbiol Infect Dis. 2008 Sep;62(1):67-80. doi: 10.1016/j.diagmicrobio.2008.04.012. Epub 2008 May 29. Diagn Microbiol Infect Dis. 2008. PMID: 18513913
-
Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.Cornea. 2015 Jun;34(6):698-703. doi: 10.1097/ICO.0000000000000431. Cornea. 2015. PMID: 25811722 Free PMC article. Review.
-
Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.J Cataract Refract Surg. 2010 Sep;36(9):1588-98. doi: 10.1016/j.jcrs.2010.06.028. J Cataract Refract Surg. 2010. PMID: 20692574 Review.
Cited by
-
Treatment-Resistant Bacterial Keratitis: Challenges and Solutions.Clin Ophthalmol. 2020 Jan 29;14:287-297. doi: 10.2147/OPTH.S181997. eCollection 2020. Clin Ophthalmol. 2020. PMID: 32099313 Free PMC article. Review.
-
Impact of photodynamic inactivation (PDI) using the photosensitizer chlorin e6 on viability, apoptosis, and proliferation of human corneal endothelial cells.Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1199-204. doi: 10.1007/s00417-012-2239-6. Epub 2012 Dec 22. Graefes Arch Clin Exp Ophthalmol. 2013. PMID: 23263624
-
Successful treatment of multidrug-resistant Pseudomonas aeruginosa keratitis with meropenem eye drops - a case report.J Ophthalmic Inflamm Infect. 2023 Sep 16;13(1):40. doi: 10.1186/s12348-023-00363-0. J Ophthalmic Inflamm Infect. 2023. PMID: 37715845 Free PMC article.
-
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.Drugs. 2011 Jan 1;71(1):89-99. doi: 10.2165/11205840-000000000-00000. Drugs. 2011. PMID: 21175242 Review.
-
In-vitro safety assessment of meropenem on human retinal pigment epithelium (RPE).Heliyon. 2024 Jul 1;10(14):e33916. doi: 10.1016/j.heliyon.2024.e33916. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39092242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical